Literature DB >> 479898

Immune complexes in myasthenia gravis.

W M Behan, P O Behan.   

Abstract

Complement components were measured and immune complexes were sought in 75 patients with myasthenia gravis. Thirty-four per cent had decreased concentrations of complement component C4, and 29% had circulating immune complexes. The greatest immunological abnormalities were found in patients with mild disease which supports recent immunoelectronmicroscopic findings.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 479898      PMCID： PMC490272          DOI： 10.1136/jnnp.42.7.595

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  23 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  Changes in serum complement activity in patients with myasthenia gravis.

Authors:  W L NASTUK; O J PLESCIA; K E OSSERMAN
Journal:  Proc Soc Exp Biol Med       Date:  1960-10

3.  Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis.

Authors:  W L NASTUK; A J STRAUSS; K E OSSERMAN
Journal:  Am J Med       Date:  1959-03       Impact factor: 4.965

4.  Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications.

Authors:  A K Lefvert; K Bergström; G Matell; P O Osterman; R Pirskanen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

5.  Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera.

Authors:  S Heinemann; J Merlie; J Lindstrom
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

6.  Antibody to acetylcholine receptor increases degradation of junctional and extrajunctional receptors in adult muscle.

Authors:  C G Reiness; C B Weinberg; Z W Hall
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

7.  Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.

Authors:  V A Lennon; M E Seybold; J M Lindstrom; C Cochrane; R Ulevitch
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

8.  Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis.

Authors:  K Sahashi; A G Engel; J M Linstrom; E H Lambert; V A Lennon
Journal:  J Neuropathol Exp Neurol       Date:  1978 Mar-Apr       Impact factor: 3.685

9.  Circulating immune complexes in multiple sclerosis and other neurological diseases.

Authors:  T G Tachovsky; R P Lisak; H Koprowski; A N Theofilopoulos; F J Dixon
Journal:  Lancet       Date:  1976-11-06       Impact factor: 79.321

10.  Multiple immune complexes and hypocomplementaemia in dermatitis herpetiformis and coeliac disease.

Authors:  I Mohammed; E J Holborow; L Fry; B R Thompson; A V Hoffbrand; J S Stewart
Journal:  Lancet       Date:  1976-09-04       Impact factor: 79.321
View more
  4 in total

1.  Immune disease and HLA associations with myasthenia gravis.

Authors:  P O Behan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

2.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

3.  Circulating immune complexes in myasthenia gravis: a study in relation to thymectomy, clinical severity and thymus histology.

Authors:  C Bartoloni; L Guidi; C Scoppetta; P Tonali; E Bartoccioni; G Flamini; G Gambassi; T Terranova
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-10       Impact factor: 10.154

4.  Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.

Authors:  Miriam L Fichtner; Michelle D Hoarty; Douangsone D Vadysirisack; Bailey Munro-Sheldon; Richard J Nowak; Kevin C O'Connor
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.